04th week of 2015 patent applcation highlights part 37 |
Patent application number | Title | Published |
20150023884 | Antiperspirant Spray Devices and Compositions - A hand held spray device is disclosed. The spray device has a body with a reservoir, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored in the reservoir. The propellant has a concentration from 72% to 90% by weight of the total fill of materials stored within the reservoir. The antiperspirant composition includes a non-volatile silicone fluid having a concentration from about 30% to about 70% by weight of the antiperspirant composition, an antiperspirant active, greater than 1% substantially inert particulates, an organoclay material and at least one liquid activation enhancer. | 2015-01-22 |
20150023885 | Antiperspirant Spray Devices and Compositions - A hand held spray device is disclosed. The spray device has a body with a reservoir to house a total fill of material, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored in the reservoir. The propellant has a concentration from 30% to 70% by weight of the total fill of materials stored within the reservoir. The antiperspirant composition includes a non-volatile silicone fluid having a concentration from about 30% to about 70% by weight of the antiperspirant composition, an antiperspirant active, an organoclay material and at least one liquid activation enhancer, and optionally a liquid fragrance material. | 2015-01-22 |
20150023886 | Antiperspirant Spray Devices and Compositions - A hand held spray device is disclosed. The spray device has a body with a reservoir to house a total fill of material, an actuator having an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir, and a propellant and antiperspirant composition stored in the reservoir. The propellant has a concentration from 72% to 90% by weight of the total fill of materials stored within the reservoir. The antiperspirant composition includes a non-volatile silicone fluid having a concentration from about 30% to about 70% by weight of the antiperspirant composition, an antiperspirant active, greater than 1% substantially inert particulates, an organoclay material, at least one liquid activation enhancer, and optionally a liquid fragrance material. | 2015-01-22 |
20150023887 | Antiperspirant Spray Devices and Compositions - A hand held spray device is disclosed. The spray device includes a body with a reservoir, an actuator with an actuator exit orifice, a valve in fluid communication with the actuator exit orifice and the reservoir and a propellant and antiperspirant composition stored in the reservoir. The propellant has a concentration from about 30% to about 70% by weight of the total fill of materials stored within the reservoir and a boiling point at 1 atmosphere from about −10° C. to about 10° C. The antiperspirant composition includes a liquid carrier and an antiperspirant active. | 2015-01-22 |
20150023888 | Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine - The invention is drawn to a novel, early interventional use of a pharmaceutical composition wherein administration of said pharmaceutical composition pre-empts the onset of migraine headaches, preferably anytime in the migraine cycle prior to pain onset. The pharmaceutical composition preferably is administered via inhalation in order to provide therapy to the subject in a timely fashion, ideally in a non-clinical setting. The pharmaceutical composition may also be administered to a subject at risk for stroke. | 2015-01-22 |
20150023889 | FLUORIDE-RESPONSIVE RIBOSWITCHS, FLUORIDE TRANSPORTERS, AND METHODS OF USE - Disclosed are compounds, compositions, and methods relating to fluoride aptamers, fluoride-responsive riboswitches, fluoride-regulated expression constructs, fluoride transporters, nucleic acids encoding fluoride transporters, expression constructs encoding fluoride transporters, and cells containing or including any combination of these. | 2015-01-22 |
20150023890 | High Fluoride Ion Oral Care Composition and Method for Maintaining Anticaries Activity - An oral care composition and method of maintaining anticaries activity of fluoride ion in an oral care composition are described. An oral care composition comprises a fluoride ion source sufficient to maintain a high fluoride content in the composition, an effective amount of a desensitizing agent and water. A method of maintaining anti caries activity of fluoride km in an oral care composition comprises providing an oral care composition comprising fluoride ions, an effective amount of a desensitizing agent and water. | 2015-01-22 |
20150023891 | NATURAL ANTI-BACTERIAL TOOTHPASTE COMPOSITION CONTAINING IMPROVEMENT IN TOOTH PAIN, ANTIBACTERIAL MOUTH AND NERVE STABILITY - The present invention relates to natural anti-bacterial toothpaste composition containing improvement in tooth pain, antibacterial mouth and nerve stability and particularly, it enables to contribute to improvement in tooth pain, antibacterial mouth and nerve stability, which represent effects of Na | 2015-01-22 |
20150023892 | MOUTH WASH COMPOSITIONS FOR DENTURE ADHESIVE REMOVAL - An antiseptic, polymer-lipid or emulsification agents-based aqueous composition can be used for intraoral removal of denture adhesive residuals. More particularly, the present invention relates to employing a polymer-lipid based or a mixture of polymer-lipids and emulsification agents or a mixture of emulsification agents and Co-emulsification agents for convenient and effective removing the denture adhesive residuals intra mouth or a combination of two ore more polymer-lipids or emulsification agents or Co-emulsification agents thereof. | 2015-01-22 |
20150023893 | METHOD OF IMPROVING THE APPEARANCE OF AGING SKIN - A method of improving the appearance of aging skin that includes applying an effective amount of artichoke leaf extract and vitamin B | 2015-01-22 |
20150023894 | Method for Producing Microcapsules with a Sun Protection Effect - A method for producing microcapsules with a sun protection effect includes mixing tetraethoxysilane (TEOS), ethanol, and water and uniformly vibrating the mixture of TEOS, ethanol, and water. The TEOS, ethanol, and water have an appropriate ratio therebetween. Nitric acid is used to adjust the mixture of TEOS, ethanol, and water to have an appropriate pH value. The mixture is placed still to hydrolyze the mixture. The hydrolyzed mixture is heated and stirred to obtain a TEOS sol. Then, the TEOS sol, Span 80, and mineral oil are mixed in an approximate ratio to obtain a microemulsified TEOS gel. The microemulsified TEOS gel is centrifuged. The upper oil phase is removed. The lower water phase and powders are sucked, filtered, and cleaned. The powders are recycled and baked. | 2015-01-22 |
20150023895 | UV Compositions Having Low Active Concentrations and High In Vivo SPF - A UV composition that contains from about 0.2% to about 2% of a UV stabilizer which is an alpha-cyanodiphenylacrylate of the general formula: | 2015-01-22 |
20150023896 | SYSTEM AND METHOD OF COMPLIMENTARY DAY/NIGHT CHILDREN'S SKIN CREAM COMPOSITIONS - A new skin care system includes day and night skin cream compositions comprising nutrients and antioxidants for use by children between six months and eighteen years of age. The day skin cream composition provides protection from UV radiation and the night skin cream composition contains no sun protection ingredients and elevated levels of nutrients and antioxidants. A child-friendly bottle for each composition can be used by young children without difficulty. A fragrance included in each composition is popular with children, and the bottle for the day composition has graphics indicating day-time use and the bottle for the night composition has graphics indicating night-time use. The day composition is applied topically each day to the face after tooth-brushing, and the night composition is applied topically to the face each night after tooth-brushing. | 2015-01-22 |
20150023897 | METHOD OF PROTECTING SKIN FROM OXIDATIVE STRESS - A method of protecting skin from an environmental stressor that includes identifying a target skin portion where protection from environmental stress is desired and topically applying a suitable skin care composition thereto. The skin composition may include a safe and effective amount of a vitamin B | 2015-01-22 |
20150023898 | Composite Particles, Method for Production Thereof, and Use Thereof - The present invention relates to composite particles comprising a carrier material as well as at least one pearlescent pigment, wherein the carrier material and the at least one pearlescent pigment are bonded to one another without an adhesive agent. In addition, the invention relates to a method for producing these composite particles as well as the use thereof. | 2015-01-22 |
20150023899 | PIGMENT MIXTURE - The present invention relates to a pigment mixture based on spherical particles having a defined particle-size distribution, and to the use thereof in paints, coatings, printing inks, security printing inks, plastics, ceramic materials, glasses, in cosmetic formulations, as tracer, as filler and for the preparation of pigment preparations and dry preparations. | 2015-01-22 |
20150023900 | AMINO ACID-MODIFIED SILOXANES, PROCESS FOR PREPARING THEM AND APPLICATION - A process for preparing amino acid-modified siloxanes that can be carried out under mild conditions is provided as well as organically modified silicones for care formulations for skin, hair and textiles that are toxicologically unobjectionable. | 2015-01-22 |
20150023901 | HAIR TREATMENT AGENTS CONTAINING 4-MORPHOLINO-METHYL-SUBSTITUTED SILICONE(S) AND THICKENING AGENT(S) - Cosmetic compositions include in a cosmetically acceptable medium at least one thickening agent and at least one 4-morpholino-methyl-substituted silicone of formula (V), in which A represents structural unit (I), (II) or (III) or an O-bound oligomeric or polymeric radical including structural units of formulae (I), (II) or (III) or half of a connecting O-atom to a structural unit (III) or represents —OH; wherein * represents a bond to one of the structural units (I), (II) or (III) or an end group B (Si-bound) or D (O-bound); B represents a group —O—Si(CH | 2015-01-22 |
20150023902 | COSMETIC USE OF AN EXTRACT OF BALANITES ALMONDS TO IMPROVE HAIR STRENGTH - The invention concerns the use of a cosmetic compound to improve hair strength, said cosmetic compound comprising as an active ingredient an extract of Balanites almonds. | 2015-01-22 |
20150023903 | ALDEHYDE GAS DEODORANT AND METHOD FOR PRODUCING SAME - To provide a method for producing an aldehyde gas deodorant which has high aldehyde deodorizing performance, and which is negative for mutagenicity and excellent in safety, and a deodorant processed product. | 2015-01-22 |
20150023904 | NEW APPLICATION OF PVP-I - The present invention relates to an application of povidone iodine (PVP-I) in the preparation of a medicine treating premature ejaculation, wherein the medicine is the compound consisting of PVP-I and any other biologically compatible carrier, such as PVP-I disinfectant or Andoful PVP-I disinfectant. The beneficial effect is: by experiment, PVP-I is proved to be able to increase patients' ILET and have a significant therapeutic effect for those suffering premature ejaculation. | 2015-01-22 |
20150023905 | SYNTHETIC MECHANICAL HEMOSTATIC COMPOSITION, METHOD OF MAKING AND USE THEREOF - A biocompatible, polymeric composition is disclosed. The composition comprises a base polymer comprising (i) a prepolymer comprising para-dioxanone (PDO) and trimethylene carbonate (TMC); and (ii) an end-graft polymer chain comprising a polylactone. Also disclosed are a method for treating bleeding from bone or bony structures using the composition, a method for filling a void or correct a defect in a bone using the composition, and a method for producing the biocompatible, polymeric composition of the present application. | 2015-01-22 |
20150023906 | FORMULATION COMPRISING A PARTICULATE CALCIUM SILICATE AND CLONOSTACHYS ROSEA FOR TREATING PLANTS - A powder plant treatment formulation for application to plants by insect vectoring includes: a plant treatment agent; a stabilizing agent bonded to the plant treatment agent for stabilizing the plant treatment agent; a moisture absorption agent for absorbing moisture from the formulation; an attracting agent for attracting the formulation to plants; and a diluent. | 2015-01-22 |
20150023907 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION - The present invention provides new methods of treatment of lentiviral infections, more particularly to treat latent retroviral HIV infections, present in cells of the infected subject, based on the re-activation of said viruses. The invention uses a combination therapy using several agents that result in strong re-activation of the latent HIV-virus that could destroy the infected cells and elicite an immune response in the subject. This could present further spread of the infection, with the ultimate aim to eradicate the virus completely in said subject. | 2015-01-22 |
20150023908 | SKIN CREAM - The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of making and using such compositions and kits comprising the skin cream therein. | 2015-01-22 |
20150023909 | LYMPH NODE-TARGETING NANOPARTICLES - Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine. | 2015-01-22 |
20150023910 | GRANULYSIN IN IMMUNOTHERAPY - Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors. | 2015-01-22 |
20150023911 | DEVICE-BASED METHODS FOR LOCALIZED DELIVERY OF CELL-FREE CARRIERS WITH STRESS-INDUCED CELLULAR FACTORS - The present invention relates to an in vitro or ex vivo method of preparing a cell-free composition, said method comprising or consisting of (a) subjecting cells to stress; and (b) collecting factors produced, preferably secreted by said cells when subjected to said stress, thereby obtaining said cell-free composition; wherein said cells are comprised in or form at least one first carrier and said collecting is effected by means of at least one second carrier which second carrier(s) is/are cell-free and concomitantly present with and spatially distinct from said first carrier; and said collecting is effected using a device comprising or consisting of (i) said first carrier(s) which first carrier(s) comprise(s) said cells or is/are suitable to hold said cells; (ii) said second carrier(s) which is cell-free; and (iii) means of subjecting said cells in said first carrier to stress; wherein first carrier(s) and second carrier(s) are positioned such that factors secreted by said cells when subjected to stress are collected in said second carrier(s), wherein means are positioned between said first and second carrier which prevent any cells and/or pathogens present in (any of) said first carrier(s) from entering into said second carrier(s). | 2015-01-22 |
20150023912 | COMBINATIONS OF ALBUMIN-BASED DRUG DELIVERY SYSTEMS - The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition. | 2015-01-22 |
20150023913 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein. | 2015-01-22 |
20150023914 | USE OF TELLURIUM COMPOUNDS FOR THE TREATMENT ACTINIC KERATOSIS - Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma and/or actinic keratosis is also provided. | 2015-01-22 |
20150023915 | TREATMENT FOR MELANOMA - The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides. | 2015-01-22 |
20150023916 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever. | 2015-01-22 |
20150023917 | TREATMENT FOR INFECTION WITH HEPATITIS B VIRUS ALONE OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND ASSOCIATED LIVER DISEASES - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis B and Hepatitis D virus infections. | 2015-01-22 |
20150023918 | LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME - Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin. | 2015-01-22 |
20150023919 | INDUCTION OF TOLERANCE IN LUNG ALLOGRAFT TRANSPLANTATION - The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing nitric oxide, increasing suppressor CD8 | 2015-01-22 |
20150023920 | NOVEL COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING CANCER METASTASIS - The invention includes a method of preventing or treating metastasis in a subject diagnosed with cancer, the method comprising determining whether at least one gene encoding one or more proteins is upregulated in a cancer tissue sample from the subject as compared to the level of expression of the at least one gene in a non-cancer control sample of the same tissue, and, if the at least one gene is upregulated in the cancer tissue sample from the subject, administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more protein depleting agents. | 2015-01-22 |
20150023921 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS - The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity. | 2015-01-22 |
20150023922 | METHODS FOR PROMOTING NEURONAL DEVELOPMENT AND/OR HEALTH - The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising a neurologic component, wherein the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include lactoferrin, zine sulfate, one or more organosulfur compound, and mixtures thereof. | 2015-01-22 |
20150023923 | METHODS FOR PROMOTING NEURONAL DEVELOPMENT AND/OR HEALTH - The present disclosure relates to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising docosahexaenoic acid and alpha-lipoic acid. The nutritional composition may further include lactoferrin, a prebiotic, a probiotic, and mixtures thereof. Additionally the present disclosure provides methods for accelerating the development of neuronal activity and/or strengthening electrochemical synapse signaling by providing the nutritional composition(s) disclosed herein to a target subject. | 2015-01-22 |
20150023924 | VARIANT AAV AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS AND TISSUES - The invention relates to adeno-associated virus (AAV) serotype AAV-Rh74 and related AAV vectors, and AAV-Rh74 and related AAV vector mediated gene transfer methods and uses. In particular, AAV-Rh74 and related AAV vectors target polynucleotides to cells, tissues or organs for expression (transcription) of genes encoding therapeutic proteins and peptides, and polynucleotides that function as or are transcribed into inhibitory nucleic acid sequences. | 2015-01-22 |
20150023925 | CONJUGATED LINOLEIC ACID-PRODUCING STRAINS OF PROBIOTIC BACTERIA AND USE THEREOF FOR THE PREPARATION OF A FOOD, DIETETIC OR PHARMACEUTICAL COMPOSITION - The present invention relates to conjugated linoleic acid (CLA)-producing strains of probiotic bacteria. In particular, the present invention relates to a selection of bacterial strains belonging to the genus | 2015-01-22 |
20150023926 | TREATMENT OF RADIATION INJURY USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of and compositions comprising, such cells. | 2015-01-22 |
20150023927 | CONVERSION OF SOMATIC CELLS INTO FUNCTIONAL SPINAL MOTOR NEURONS, AND METHODS AND USES THEREOF - The present invention provides methods of transdifferentiation of somatic cells, for example, directly converting a somatic cell of a first cell type, e.g., a fibroblast into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for converting a somatic cell, e.g., a fibroblast into a motor neuron, e.g., an induced motor neuron (iMN) with characteristics of a typical motor neuron. The present invention also relates to an isolated population comprising induced motor neurons (iMNs), compositions and their use in the treatment of motor neuron diseases such as ALS and SMA. In particular, the present invention relates to direct conversion of a somatic cell to an induced motor neuron (iMN) having motor neuron characteristics by increasing the protein expression of at least three motor-neuron inducing (MN-inducing) factors selected from Lhx3, Ascl1, Brn2, Myt1l, Isl1, Hb9, Ngn2 or NeuroD1 in a somatic cell, e.g., a fibroblast to convert the fibroblast to an induced motor neuron (iMN) which exhibits at least two characteristics of an endogenous motor neuron. | 2015-01-22 |
20150023928 | STEM CELL PREPARATIONS AND METHODS OF USE - The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. In one aspect, the invention has been developed as a method for preparing and culturing BSC. | 2015-01-22 |
20150023929 | ORAL UNIT DOSAGE FORMS AND USES OF SAME FOR THE TREATMENT OF GAUCHER DISEASE - A method of treating Gaucher's disease in a subject in need thereof is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerecbrosidase (GCD) comprised in plant cells, wherein said therapeutically effective amount of GCD corresponds to 1-1920 units/Kg/14 days, thereby treating Gaucher's disease. Also provide unit dosage forms which comprise the glucocerecbrosidase (GCD) comprised in plant cells. | 2015-01-22 |
20150023930 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF - Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome. | 2015-01-22 |
20150023931 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS - Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit. | 2015-01-22 |
20150023932 | ENGINEERED PEPTIDE (EP)-DIRECTED PROTEIN INTERCELLULAR DELIVERY SYSTEM AND USES THEREOF - The present invention provides an intercellular protein delivery system comprising an engineered peptide (EP), composed of secretion part (SP) and nuclear translocation part (NTP), a functional or therapeutic protein (FP), cells that express the fusion proteins and cells that accept the fusion proteins. The system can be used in vivo or in vitro to sustainably supply proteins of interest for cellular reprogramming, cellular differentiation and cell-based protein therapies. | 2015-01-22 |
20150023933 | Materials and Methods Relating to Packaging Cell Lines - Lentiviral packaging cells and methods for producing the same are provided herein. Specifically, lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are provided. Methods for producing lentiviral packaging cells capable of producing lentiviral vector suitable for use in clinical trials are described. | 2015-01-22 |
20150023934 | GENERATION OF EPITHELIAL CELLS AND ORGAN TISSUE IN VIVO BY REPROGRAMMING AND USES THEREOF - The present invention encompasses methods for reprogramming fibroblast cells in culture, which are able to generate generic epithelial cells therefrom. | 2015-01-22 |
20150023935 | Reprogramming of Aged Adult Stem Cells - A method of reprogramming aged human or animal adult stem cells (AASC), comprising the steps of (a) collecting young adult stem cells (YASC) from the blood of a donor wherein the donor is less than 40 years old; (b) dissolving at least a portion of membranes of said YASC to release an intracellular matrix (ICM) thereof; (c) applying a supernatant of said ICM to a culture of AASC; and (d) following exposure of said AASC to said supernatant for a bioactively sufficient period, infusing such an exposed AASC to the donor thereof. A method comprising the steps of (a) collecting young adult stem cells (YASC) from the blood of a donor wherein the donor is less than 40 years old; (b) dissolving at least a portion of membranes of said YASC to release an intracellular matrix (ICM) thereof; (c) applying a supernatant of said ICM to a culture of aged adult stem cells (AASC) to produce exposed AASC; (d) recovering at least a portion of the exposed AASC; and (e) introducing the exposed AASC to the donor wherein the donor is greater than 40 years of age and is diagnosed with a disorder selected from the group consisting of AIDS, an age-related disease, and an immune deficiency disorder. | 2015-01-22 |
20150023936 | STRAIN OF LACTOBACILLUS ACIDOPHILUS HAVING ANALGESIC PROPERTIES IN THE GASTROINTESTINAL SYSTEM - The invention proposes the use of at least one strain of | 2015-01-22 |
20150023937 | HISTONE DEACETYLASE (HDAC) INHIBITOR UP-REGULATES CAR EXPRESSION AND TARGETED ANTIGEN INTENSITY, INCREASING ANTITUMOR EFFICACY - Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor. | 2015-01-22 |
20150023938 | METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENS - Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material. | 2015-01-22 |
20150023939 | APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS - An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient. | 2015-01-22 |
20150023940 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described. | 2015-01-22 |
20150023941 | Compositions Comprising Sugar-Cysteine Products - The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same. | 2015-01-22 |
20150023942 | COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL OUTGROWTH - Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration. | 2015-01-22 |
20150023943 | REF Nuclease for Site-Specific REF-Mediated DNA Cleavage - Purified Ref polypeptides with increased nuclease site-specific targeting activity, recombinant nucleic acids and cells for expression of such Ref polypeptides, and methods for using the Ref polypeptides in combination with RecA protein and variants thereof to effect targeted nuclease cleavage of a DNA duplex are disclosed. | 2015-01-22 |
20150023944 | Method of Treating and Diagnosing Parkinson's Disease and Related Dysautonomic Disorders - A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder. | 2015-01-22 |
20150023945 | Lysozymes - The present invention is directed to lysozyme variants and nucleotide sequences encoding same. The lysozyme variants have antimicrobial and/or lysozyme activity and comprise an alteration of an amino acid sequence at one or more positions. The present invention is also directed to methods for producing and of using the | 2015-01-22 |
20150023946 | Combined Use of a Sulfated Glycosaminoglycan and a Hyaluronidase for Improving the Bioavailability of Factor VIII - The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by co-adminstration of a sulfated glycosaminoglycan and a hyaluronidase. | 2015-01-22 |
20150023947 | MEDICINAL PRODUCTS FOR THE TREATMENT OF BLOOD COAGULATION DISORDERS - A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation. | 2015-01-22 |
20150023948 | FORMULATION FOR TREATMENT OF IRRITABLE BOWEL DISEASE - The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations. | 2015-01-22 |
20150023949 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER - Methods for treatment and diagnosis of pervasive developmental disorders in humans are described. | 2015-01-22 |
20150023950 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System - The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. | 2015-01-22 |
20150023951 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 2015-01-22 |
20150023952 | ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF - The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs. | 2015-01-22 |
20150023953 | METHOD OF TREATING CANCER - Methods are provided for treating cancer in a patient in need thereof with a HER2 inhibitor, where such patients have certain polymorphisms in VEGFA, VEGFR or IGF1R. | 2015-01-22 |
20150023954 | POTENTIATING ANTIBODY-INDUCED COMPLEMENT-MEDIATED CYTOTOXICITY VIA PI3K INHIBITION - Methodologies and technologies for potentiating antibody-based cancer treatments by increasing complement-mediated cell cytotoxicity are disclosed. Further provided are methodologies and technologies for overcoming ineffective treatments correlated with and/or caused by sub-lytic levels of complement-activating monoclonal antibodies (“mAb”) against cancer antigens or cancer antigens with low tumor cell density. While detectable levels of passively administered or vaccine-induced mAb against some antigens are able to delay or prevent tumor growth, low levels of mAb induce sublytic levels of complement activation and accelerate tumor growth. This complement-mediated accelerated tumor growth initiated by low mAb levels results in activation of the PI3K/AKT survival pathway. Methodologies and technologies relating to administration of PI3K inhibitors to overcome low dose mAb-initiated, complement-mediated PI3K activation and accelerated tumor growth are disclosed. | 2015-01-22 |
20150023955 | Treatment and Diagnosis of Melanoma - The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods. | 2015-01-22 |
20150023956 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibodies provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis III (MPS-III). The fusion antibodies provided herein comprise N-sulfoglucosamine sulfohydrolase (SGSH), alpha-N-acetylgulcosaminidase (NAGLU), heparin-alpha-glucosaminide N-acetyltransferase (HGSNAT), or N-acetylglucosamine-6-sulfatase (GNS). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein. | 2015-01-22 |
20150023957 | SAA DOMAIN-SPECIFIC ANTIBODIES AND PEPTIDE ANTAGONISTS AND USE THEREOF TO TREAT INFLAMMATORY DISEASES - Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided. | 2015-01-22 |
20150023958 | FUSION POLYPEPTIDE INHIBITING VEGF-C, VEGF-D AND/OR ANGIOPOIETIN-2, AND USE THEREOF - A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof. | 2015-01-22 |
20150023959 | CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF - The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins. | 2015-01-22 |
20150023960 | Compositions and Methods of Use for Treating Metabolic Disorders - Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 2015-01-22 |
20150023961 | METHODS OF MODULATING IMMUNOLOGICAL RESPONSES BY ADMINISTERING TRUNCATED BAFF RECEPTORS - The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders. | 2015-01-22 |
20150023962 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2015-01-22 |
20150023963 | METHOD FOR THE PRODUCTION OF VARIABLE DOMAINS - The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties. | 2015-01-22 |
20150023964 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. | 2015-01-22 |
20150023965 | METHODS OF TREATING UROTHELIAL CARCINOMA - Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed. | 2015-01-22 |
20150023966 | COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES - This disclosure relates to combination therapies comprising anti- | 2015-01-22 |
20150023967 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 2015-01-22 |
20150023968 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING HYPERTHYROIDISM IN COMPANION ANIMALS - An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula. | 2015-01-22 |
20150023969 | POLYPEPTIDES AND IMMUNIZING COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a | 2015-01-22 |
20150023970 | ACTRIIB PROTEINS AND VARIANTS AND USES THEREFORE RELATING TO UTROPHIN INDUCTION FOR MUSCULAR DYSTROPHY THERAPY - In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. | 2015-01-22 |
20150023971 | Modulation of Activity of Proneurotrophins - The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual. | 2015-01-22 |
20150023972 | COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES - The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS. | 2015-01-22 |
20150023973 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING ANGIOGENIC DISEASES COMPRISING INHIBITORS OF NUP153 GENE EXPRESSION OR NUP153 ACTIVITY AS ACTIVE INGREDIENT - The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or the NUP153 activity reduces export of mRNA of a pro-angiogenic factor (VEGF, HGF and bFGF) from nucleus. In addition, inhibition of the NUP153 gene expression or the NUP153 activity has effect that angiogenesis are inhibited by inhibition of invasion and tube formation in a dose-dependent manner without showing toxicity. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating a variety of angiogenesis-related diseases, and the method for screening of the present invention may be valuably used in finding a new agent for preventing or treating angiogenic diseases. | 2015-01-22 |
20150023974 | TOLL-LIKE RECEPTOR 2 BINDING EPITOPE AND BINDING MEMBER THERETO - The present invention relates to the identification of a TLR2 binding epitope wherein binding of a binding member to the epitope serves to inhibit TLR2 activation and/or signalling. Polypeptide fragments of TLR2 and three-dimensional structures comprising one or more amino acid residues His318, Pro320, Gln321 or Arg321, Tyr323, Lys347, Phe349, Leu371, Glu375, Tyr376 and His398 of TLR2 which define the identified epitope are provided for use in generating binding members. Also provided are binding members which bind to the identified epitope and methods of using same for the treatment and/or prevention of conditions associated with TLR2 activation and/or signalling. | 2015-01-22 |
20150023975 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) - Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1. MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases. | 2015-01-22 |
20150023976 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 2015-01-22 |
20150023977 | PROTEIN FORMULATIONS AND METHODS OF MAKING SAME - The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality. | 2015-01-22 |
20150023978 | ANTI MIF ANTIBODIES - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions. | 2015-01-22 |
20150023979 | Antibodies Against E7 Protein of Human Papilloma Virus (HPV) - The invention discloses a method for preparing Human Papilloma Virus protein E7 antigen (HPV E7 antigen) comprising the following steps: —providing a purified preparation of HPV protein E7; —phosphorylating the HPV protein E7 in the preparation; —purifying the phosphorylated E7 protein with an anion exchange chromatography, wherein the phosphorylated E7 protein is separated from the non-phosphorylated E7 protein by a step wherein the non-phosphorylated E7 protein stays bound to an anion exchanger during the anion exchange chromatography whereas the phosphorylated E7 protein is obtained in the eluate of the anion exchange chromatography, thereby—obtaining a purified preparation of a phosphorylated HPV protein E7 antigen. The invention further discloses antibodies specific to this antigen, a kit and method for using such antibodies in clinical diagnostics and methods for generation of such antibodies. | 2015-01-22 |
20150023980 | COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES - The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS. | 2015-01-22 |
20150023981 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME - The present invention relates generally to a method of modulating graft functionality. More specifically, the present invention relates to a method of downregulating the onset or progression of graft dysfunction by downregulating the functional level of activin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by graft dysfunction, such as the primary graft dysfunction associated with organ transplantation. | 2015-01-22 |
20150023982 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2015-01-22 |
20150023983 | RECOMBINANT VAPA AND VAPC PEPTIDES AND USES THEREOF - The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a | 2015-01-22 |